Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry LuminaryGlobeNewsWire • 04/17/23
Aflibercept 8 mg and EYLEA® (aflibercept) Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal DiseasesGlobeNewsWire • 04/17/23
Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023GlobeNewsWire • 04/03/23
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)GlobeNewsWire • 03/29/23
Sonoma Bio inks $75M deal with Regeneron to advance cell therapies against autoimmunityGeekWire • 03/28/23
Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune DiseasesGlobeNewsWire • 03/28/23
Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune DiseasesBusiness Wire • 03/28/23
Biotech Growth Stock Soars To New Highs On Lung Disease BreakthroughInvestors Business Daily • 03/24/23
Regeneron (REGN) Soars 6.8%: Is Further Upside Left in the Stock?Zacks Investment Research • 03/24/23
Regeneron Breaks Out On Home Run In 'Smoker's Lung' As Sanofi SoarsInvestors Business Daily • 03/23/23
Sanofi, Regeneron shares pop more than 6% after data shows asthma drug Dupixent may also treat COPDCNBC • 03/23/23